Allogenic human mesenchymal stem cells may be safe and effective in patients with non-ischemic dilated cardiomyopathy compared to autologous stem cells, according to the results of the POSEIDON-DCM Trial presented Nov. 14 during AHA 2016 and simultaneously published in the Journal of the American College of Cardiology.

Joshua M. Hare, MD, FACC, et al., randomized 37 patients with non-ischemic dilated cardiomyopathy to receive either allogenic or autologous bone marrow-derived human mesenchymal stem cells by transendocardial stem cell injection. Patients were evaluated at baseline, 30-days, three, six and 12 months for safety and efficacy endpoints.

The results of the study show that the rate of major adverse cardiac events was lower in patients who received allogenic stem cells versus autologous. Ejection fraction increased in the allogenic group by 8 units, compared to 5.4 units in the autologous group. Further, at 12-months, the incidence of serious adverse events was 28.2 percent in the allogenic group versus 63.5 percent in the autologous group.

“The findings must be viewed as preliminary given the small number of patients enrolled,” commented Kim A. Eagle, MD, MACC, editor-in-chief of ACC.org.

Keywords: AHA16, American Heart Association, AHA Annual Scientific Sessions, Cardiomyopathy, Dilated, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Safety, Transplantation, Autologous

< Back to Listings